HUMA — Humacyte, Inc.

Earnings Call Summary for Humacyte (Q3 2025)

1. Key Financial Results and Metrics:

• Revenue: Q3 2025 revenue was $0.8 million, with $0.7 million from U.S. sales of Symvess and $0.1 million from a research collaboration. For the nine months ending September 30, 2025, total revenue was $1.6 million.
• Cost of Goods Sold (COGS): COGS for Q3 was $0.3 million, and $0.6 million for the nine months.
• Research and Development (R&D) Expenses: R&D expenses decreased to $17.3 million in Q3 2025 from $22.9 million in Q3 2024, and $54.7 million for the nine months, down from $67.9 million in the prior year.
• Selling, General and Administrative (SG&A) Expenses: SG&A was $7.6 million for Q3 2025, slightly up from $7.3 million year-over-year.
• Net Loss: The net loss for Q3 was $17.5 million, improved from a loss of $39.2 million in Q3 2024. For the nine months, the net loss was $16.0 million, down from $127.8 million in the previous year.
• Cash Position: As of September 30, 2025, cash and equivalents stood at $19.8 million. Following a recent stock sale, the company added approximately $56.5 million, providing a cash runway exceeding 12 months.

2. Strategic Updates and Business Highlights:

• Symvess Launch: The commercial launch of Symvess is gaining traction, with 25 hospitals completing the Value Analysis Committee (VAC) process, representing 92 hospitals eligible to purchase. Product sales increased significantly to $703,000 from $100,000 in the previous quarter.
• Clinical Studies: Positive outcomes from multiple studies support Symvess in treating vascular trauma, with publications highlighting its effectiveness and safety.
• Dialysis Access Program: Results from the V007 Phase III trial were presented, showing superior duration of use compared to autogenous fistula in high-need subgroups. Plans for a supplemental BLA submission in the second half of 2026 are in place, pending interim analysis results from the V012 trial.
• Intellectual Property Expansion: A new U.S. patent for a bioengineered esophagus was granted, enhancing the company’s IP portfolio.

3. Forward Guidance and Outlook:

• The company remains optimistic about growth and value generation through its commercial efforts and pipeline programs. They anticipate continued adoption of Symvess and plan to file for additional indications in dialysis access by late 2026.
• The interim analysis for the V012 trial is expected around April 2026, which will inform the BLA submission timeline.

4. Bad News, Challenges, or Points of Concern:

• NTAP Submission: Humacyte has opted not to resubmit for the New Technology Add-on Payment (NTAP) for trauma, as the initial decision by CMS deemed Symvess not novel, which may limit reimbursement opportunities.
• Market Sensitivity: The company noted price sensitivity in the hospital market, which could impact future sales and adoption rates.
• Cash Burn: While cash burn has decreased, the company reported a net cash used in operating expenses of $78.9 million for the first nine months of 2025, indicating ongoing financial pressures.

5. Notable Q&A Insights:

• Surgeons are increasingly adopting Symvess, with many hospitals seeing repeat orders, although initial stocking orders are typically low.
• The reduction in Symvess pricing has accelerated the VAC approval process, making it easier for hospitals to consider the product.
• The company is strategically expanding its sales force to target both trauma and dialysis access markets, leveraging existing relationships with vascular surgeons.
• Discussions regarding real-world outcomes and post-approval studies are ongoing, with a registry study expected to start in early 2026.

Overall, Humacyte's Q3 2025 results reflect significant progress in commercializing Symvess, bolstered by positive clinical data and strategic initiatives, despite challenges related to reimbursement and market dynamics.